Market Cap : 229.25 M | Enterprise Value : 154.88 M | PE Ratio : At Loss | PB Ratio : 2.89 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2022-05-20), VistaGen Therapeutics's share price is $1.11. VistaGen Therapeutics's Tangible Book per Share of Dec. 2021 for the quarter that ended in Dec. 2021 was $0.39. Hence, VistaGen Therapeutics's Price to Tangible Book Ratio of today is 2.87.
The historical rank and industry rank for VistaGen Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, VistaGen Therapeutics's highest Price to Tangible Book Ratio was 28.41. The lowest was 2.44. And the median was 7.71.
VTGN's Price-to-Tangible-Book is ranked worse thanA closely related ratio is called PB Ratio. As of today, VistaGen Therapeutics's share price is $1.11. VistaGen Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2021 was $0.39. Hence, VistaGen Therapeutics's P/B Ratio of today is 2.87.
The historical data trend for VistaGen Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VistaGen Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Price-to-Tangible-Book falls into.
VistaGen Therapeutics's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Dec. 2021 ) |
= | 1.11 | / | 0.387 | |
= | 2.87 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of VistaGen Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Fool 2021-06-30
By Zacks 2022-02-10
By Zacks 2021-11-10
By tipranks.com 2022-02-13
By Zacks 2021-10-20
By Seekingalpha 2021-06-29
By Zacks 2021-06-16
By tipranks.com 2022-03-03
By Zacks 2021-08-12
By Zacks 2021-02-11
By Seekingalpha 2021-11-10
By Zacks 2022-04-05